Literature DB >> 30951497

Biomarker-assisted identification of sepsis-related acute liver impairment: a frequent and deadly condition in critically ill patients.

Jens-Ulrik Stæhr Jensen1,2, Lars Peters1, Theis S Itenov1,3, Morten Bestle3,4, Katrin M Thormar5,6, Thomas T Mohr4,6, Bettina Lundgren7, Jesper Grarup1, Jens D Lundgren1.   

Abstract

Background The prognostic impact of mild/moderate liver impairment among critically ill patients is not known. We aimed to determine whether acute liver impairment, as measured by several biomarkers, (i) is frequent, (ii) influences prognosis and (iii) to determine whether such an effect is specific for infected critically ill patients. Methods A biomarker and clinical cohort study based on a randomized controlled trial. All-cause mortality was the primary endpoint. Biomarkers hyaluronic acid (HA), bilirubin, albumin, alkaline phosphatase and the international normalized ratio (INR) were determined. Multivariable statistics were applied to estimate risk increase according to liver biomarker increase at baseline and the model was adjusted for age, APACHE II, severe sepsis/septic shock vs. milder infection, chronic alcohol abuse Charlson's co-morbidity index, cancer disease, surgical or medical patient, body mass index, sex, estimated glomerular filtration rate, mechanical ventilation and the other biomarkers. Time-to-event graphs were used. The patients were critically ill patients (n = 1096) from nine mixed medical/surgical intensive care units without known hepatobiliary disease. Results HA levels differed between infected patients (median 210.8 ng/mL [IQR: 93.2-556.6]) vs. the non-infected (median 56.8 ng/mL [IQR: 31.9-116.8], p < 0.001). Serum HA quartiles 2, 3 and 4 were independent predictors of 90-day all-cause mortality for the entire population (infected and non-infected). However, the signal was driven by the infected patients (positive interaction test, no signal in non-infected patients). Among infected patients, HA quartiles corresponded directly to the 90-day risk of dying: 1st quartile: 57/192 = 29.7%, 2nd quartile: 84/194 = 43.3%, 3rd quartile: 90/193 = 46.6%, 4th quartile: 101/192 = 52.3 %, p for trend: <0.0001. This finding was confirmed in adjusted analyses: hazard ratio vs. 1st quartile: 2nd quartile: 1.3 [0.9-1.8], p = 0.14, 3rd quartile: 1.5 [1.1-2.2], p = 0.02, 4th quartile: 1.9 [1.3-2.6], p < 0.0001). High bilirubin was also an independent predictor of mortality. Conclusions Among infected critically ill patients, subtle liver impairment, (elevated HA and bilirubin), was associated with a progressive and highly increased risk of death for the patient; this was robust to adjustment for other predictors of mortality. HA can identify patients at high risk.

Entities:  

Keywords:  biomarkers; infection; liver impairment; mortality

Mesh:

Substances:

Year:  2019        PMID: 30951497     DOI: 10.1515/cclm-2018-1350

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  6 in total

1.  Liver impairment in critical illness and sepsis: the dawn of new biomarkers?

Authors:  Martin Kluge; Frank Tacke
Journal:  Ann Transl Med       Date:  2019-12

2.  International Normalized Ratio to Albumin Ratio (PTAR): An Objective Risk Stratification Tool in Patients with Sepsis.

Authors:  Shaoxiong Wang; Shuizi Ding; Hong Luo; Xiangping Chai
Journal:  Int J Gen Med       Date:  2021-05-12

3.  Proteomic atlas of organ vasculopathies triggered by Staphylococcus aureus sepsis.

Authors:  Alejandro Gómez Toledo; Gregory Golden; Alexandre Rosa Campos; Hector Cuello; James Sorrentino; Nathan Lewis; Nissi Varki; Victor Nizet; Jeffrey W Smith; Jeffrey D Esko
Journal:  Nat Commun       Date:  2019-10-11       Impact factor: 14.919

Review 4.  Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review.

Authors:  Maria Sanz Codina; Markus Zeitlinger
Journal:  Clin Pharmacokinet       Date:  2022-02-25       Impact factor: 5.577

5.  Development and validation of a score to predict mortality in ICU patients with sepsis: a multicenter retrospective study.

Authors:  Jie Weng; Ruonan Hou; Xiaoming Zhou; Zhe Xu; Zhiliang Zhou; Peng Wang; Liang Wang; Chan Chen; Jinyu Wu; Zhiyi Wang
Journal:  J Transl Med       Date:  2021-07-29       Impact factor: 5.531

6.  Incidence, Clinical Characteristics and Outcomes of Early Hyperbilirubinemia in Critically Ill Patients: Insights From the MARS Study.

Authors:  Jenny Juschten; Lieuwe D J Bos; Harm-Jan de Grooth; Ulrich Beuers; Armand R J Girbes; Nicole P Juffermans; Stephan A Loer; Tom van der Poll; Olaf L Cremer; Marc J M Bonten; Marcus J Schultz; Pieter Roel Tuinman
Journal:  Shock       Date:  2022-02-01       Impact factor: 3.454

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.